Peer-reviewed publicaties
Ahmed, S. et al.
A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International Journal of Infectious Diseases, 2020; December
Alam, M. T. et al.
Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study. European Journal of Medical & Health Sciences, 2020; vol. 2 (6)
Alam, M.T. et al.
A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. Journal of Bangladesh College of Physicians and Surgeons, 2020; vol. 38: p.10-15
Al-Kuraishy, H. et al.
Is ivermectin–Azithromycin combination the next step for COVID-19?. Biomed Biotechnol Res J, 2020; vol. 4: S1:101-3
Aref, Z. et al.
Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19. International Journal of Nanomedicine, 2021; vol. 16: p. 4063-4072
Arévalo, A. et al.
Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Scientific Reports, 2021; vol. 11 (7132)
Andrade, B. et al.
Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review. Frontiers in Pharmocology, 2020
Azam, F. et al.
An in-silico analysis of ivermectin interaction with potential SARS-CoV-2 targets and host nuclear importin α. Journal of Biomolocular Structure and Dynamics, 2020
Azam, N.
Some home remedies used for treatment of COVID-19 in Bangladesh. Journal of Medicinal Plant Studies.
2020; vol. 8(4): p.27-32
Babalola, O. et al.
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. QJM: An International Journal of Medicine, 2021; hcab035
Behera, P. et al.
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. PLoS ONE, 2021; vol.16(2): e0247163
Bello, M.
Elucidation of the inhibitory activity of ivermectin with host nuclear importin α and several SARS-CoV-2 targets. Journal of Biomolecular Structure and Dynamics, 2021
Bernigaud, C. et al.
Bénéfice de l’ivermectine: de la gale à la COVID-19, un exemple de sérendipité. Annales de Dermatologie et de Vénéréologie, 2020; vol. 147 (12): A194
Bhowmick, S. et al.
Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review. Drug Safety, 2021
Caly, L. et al.
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 2020; vol. 178 (June)
Campillo, J. et al.
Serious adverse reactions associated with ivermectin: A systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World. PLoS ONE, 2021; vol. 15(4)
Camprubi, D. et al.
Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. PLoS ONE, 2020; vol. 15 (11)
Carvallo, H.
Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel. Journal of Biomedical Research and Clinical Investigation, 2020; vol. 2 (1)
Chacar, A. et al.
Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients. Internation Journal of Sciences, 2020; vol. 9 (September): p.31-35
Chaccour, C. et al.
The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine, 2021; vol. 32
Choudury, A. et al.
Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach. Future Virology, 2021; vol. 16 (4): p. 277 - 291
Chowdhury, A. et al.
A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients. Eurasian Journal on Medicine and Oncology, 2021; vol. 5 (1): p. 63-70
Elalfy, H. et al.
Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID‐19. Journal of Medical Virology, 2021
Elkholy, K. et al.
Ivermectin: A Closer Look at a Potential Remedy. Cureus, 2020; vol. 12 (9)
Errecalde, J. et al.
Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model. Journal of Pharmaceutical Sciences, 2021
Espitia-Hernandez, G.
Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study. Biomedical Research: An International Journal of Medical Sciences, 2020; vol. 31 (5)
Eweas, H. et al.
Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2. Frontiers in Microbiology, 2021
Faisal, R. et al.
Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19. Professional Medical Journal, 2021; vol. 28(5): p. 737-741
Fonseca, S. et al.
Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis. Travel Medicine and Infectious Diseases, 2020; vol. 38
Galan, L. et al.
Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. Pathogens and Global Health, 2021
Guerrero, E. et al.
COVID-19: The Ivermectin African Enigma. Damage Control Surgery (I), 2020; vol. 51(4)
Guzzo, C. et al.
Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects. Journal of Clinical Pharmacology, 2002; vol. 42(10): p.1122-1133
Harianto, T. et al.
Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies. Reviews in Medical Virology, 2021;
Heidary, F. & R. Gharebaghi,
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. The Journal of Antibiotics, 2020; vol. 73: p. 593-602
Hellwig, M. & A. Maya
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. International Journal of Antimicrobial Agents, 2020; November
Hussain, S.
Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh. International Journal of Molecular and Immuno Oncology, 2020; December
Jans, D. & K. Wagstaff
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal? Cells, 2020; vol. 9(9)
Jittamala, P. et al.
A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication? PLoS Neglected Tropical Diseases, 2021; vol. 15 (3): e0009144
Kahn, S. et al.
Ivermectin for COVID-19: A broad-spectrum veterinary endectocide with antiviral activity. Journal of Food and Animal Sciences, 2020; vol. 1(1): p.1-6
Kaur, H.
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacological Reports, 2021; e2265
Kory, P. et al.
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. American Journal of Therapeutics, 2021; vol. 29(3): p. e299-e318
Kow, C. et al.
The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacological Reports, 2021
Kumar, S. et al.
Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity. Computational and Structural Biotechnology Journal, 2021
Lehrer, S. & P. Rheinstein
Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2. In Vivo, 2020; vol. 34(5): p. 3023-3026
Li, N. et al.
Quantitative proteomics reveals a broad‐spectrum antiviral property of ivermectin, benefiting for COVID‐19 treatment. Journal of Cellular Physiology, 2020; p.1-17
Lima-Morales, R. et al.
Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico. International Journal of Infectious Diseases, 2021; vol.105: p. 598 - 605
López-Medina, E. et al.
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19. JAMA, 2021
Madrid, R. et al.
Safety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation. Heliyon, 2021; vol. 7(1)
Mahmud, R. et al.
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. Journal of International Medical Research, 2021; mei
McCullough, P. et al.
Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Reviews in Cardiovascular Medicine, 2020; vol 21 (4): p.517-530
Mittal, N & R. Mittal.
Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19? Medical Hypotheses, 2020; November
Mody, V. et al.
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Communications Biology, 2021; 4: art. 93
Momekov, G. & D. Momekova
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnology & Biotechnological Equipment, 2020; vol. 34 (1)
Morgenstern, J. et al.
The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020. Journal of Clinical Trials, 2021; vol. 11 (9)
Navarro, M. et al.
Safety of high-dose ivermectin: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2020; vol. 75(4): p.827-834
Núñez, A. et al.
Therapeutic Efficacy of Ivermectin as an Adjuvant in the Treatment of Patients with COVID-19 Study conducted at the Social Security Institute for Workers of the State of Chiapas, ISSTECH, Mexico. International Journal of Innovative Science and Research Technology, 2020; vol. 5(7): p.211-215
Okomuş, N. et al.
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. BMC Infectious Diseases, 2021; art. 411
Padhy, B. et al.
Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. Journal of Pharmacy and Pharmaceutical Sciences, 2020; 23: p.462-469
Pareja-Cruz, A. & J. Luque-Espino
Seguridad y eficacia de ivermectina en tiempos de COVID-19. Horizonte Médico (Lima), 2021; vol. 21 (1): e1393
Procter, B. et al.
Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. Reviews in Cardiovascular Medicine, 2020; vol. 21 (4): p. 611-614
Podder, C.S.
Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. I.M.C. Journal of Medical Science, 2020; vol. 14 (2)
Pott-Junior, H. et al.
Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology Reports, 2021; vol. 8: p. 505-510
Rajter, J. et al.
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The ICON Study. CHEST, 2020; october
Saha, J. & Md. Raihan
The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2. Structural Chemistry, 2021
Samaha, A. et al.
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon, 2021; vol. 13 (989)
Schmith, V. et al.
The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin. Pharmocol Ther., 2020; May
Shouman, W.
Use of Ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt : A Randomised clinical trial. Journal of Clinical and Diagnostic Research, 2021; vol. 15 (2): p. 27-32
Spoorthi, V & S. Sasank
Utility of Ivermectin and Doxycycline combination for the treatment of SARS-CoV-2. IAIM, 2020; vol. 7(10): p.177-182.
Surnar, B.
Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19. ACS Pharmalogical & Translational Science, 2020; December
Taguchi, Y. & T. Turki
A new advanced in silico drug discovery method for novel coronavirus (SARS-CoV-2) with tensor decomposition-based unsupervised feature extraction. PLoS ONE, 2020; vol 15 (9)
Udofia, I. et al.
In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV. Netw Model Anal Health Inform Bioinform. 2021; vol. 10(1)
Yang, S. et al.
The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Research, 2020; vol. 177
